Trulicity is a medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to reduce blood sugar levels by stimulating the release of insulin from the pancreas. Trulicity is administered as a once-weekly subcutaneous injection and is available in both 0.75 mg and 1.5 mg doses. It is also used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes and established cardiovascular disease. Trulicity is part of a larger market of endocrine and metabolic disorder drugs, which includes other GLP-1 receptor agonists, such as Victoza and Bydureon, as well as insulin, sulfonylureas, and thiazolidinediones. These medications are used to treat a variety of endocrine and metabolic disorders, including diabetes, obesity, and thyroid disorders. Some companies in the Trulicity market include Eli Lilly and Company, Novo Nordisk, Merck & Co., and Sanofi. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
